Cargando…

Is dopaminergic medication dose associated with self-reported bruxism in Parkinson’s disease? A cross-sectional, questionnaire-based study

OBJECTIVES: It is not clear whether dopaminergic medication influences bruxism behaviour in patients with Parkinson’s disease (PD). Therefore, the aims are to investigate (i) the prevalence of possible (i.e., self-reported) bruxism (sleep and awake) in PD patients, and (ii) whether the use of dopami...

Descripción completa

Detalles Bibliográficos
Autores principales: Verhoeff, M. C., Koutris, M., van Selms, M. K. A., Brandwijk, A. N., Heres, M. S., Berendse, H. W., van Dijk, K. D., Lobbezoo, F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8060196/
https://www.ncbi.nlm.nih.gov/pubmed/32918624
http://dx.doi.org/10.1007/s00784-020-03566-0
_version_ 1783681311579308032
author Verhoeff, M. C.
Koutris, M.
van Selms, M. K. A.
Brandwijk, A. N.
Heres, M. S.
Berendse, H. W.
van Dijk, K. D.
Lobbezoo, F.
author_facet Verhoeff, M. C.
Koutris, M.
van Selms, M. K. A.
Brandwijk, A. N.
Heres, M. S.
Berendse, H. W.
van Dijk, K. D.
Lobbezoo, F.
author_sort Verhoeff, M. C.
collection PubMed
description OBJECTIVES: It is not clear whether dopaminergic medication influences bruxism behaviour in patients with Parkinson’s disease (PD). Therefore, the aims are to investigate (i) the prevalence of possible (i.e., self-reported) bruxism (sleep and awake) in PD patients, and (ii) whether the use of dopaminergic medication and other factors (viz., demographic characteristics, PD-related factors, and possible consequences of bruxism) are associated with possible bruxism (sleep or awake). MATERIALS AND METHODS: This study concerns a secondary analysis of an earlier published study. Three hundred ninety-five PD patients (67.9 ± 8.6 years of age; 58.7% males) were included. The levodopa equivalent daily dosage (LEDD) was used as a measure of the dopaminergic medication level. Subsequently, a logistic regression analysis was performed for the dependent variables ‘awake bruxism’ and ‘sleep bruxism’, with the following predictors: gender, age, LEDD, time since PD diagnosis, temporomandibular disorder (TMD) pain, jaw locks, and tooth wear. RESULTS: The prevalence of possible awake and sleep bruxism was 46.0% and 24.3%, respectively. Awake bruxism was associated with sleep bruxism (OR = 8.52; 95% CI 3.56–20.40), TMD pain (OR = 4.51; 95% CI 2.31–8.79), and tooth wear (OR = 1.87; 95% CI 1.02–3.43). Sleep bruxism was associated with tooth wear (OR = 12.49; 95% CI 4.97–31.38) and awake bruxism (OR = 9.48; 95% CI 4.24–21.19). Dopaminergic medication dose was not associated with awake bruxism (OR = 1.0; 95% CI 0.99–1.00) or sleep bruxism (OR = 1.0; 95% CI 0.99–1.00). CONCLUSION: Bruxism is a common condition in PD patients, but is not associated with the dopaminergic medication dose. CLINICAL RELEVANCE: (Oral) health care providers should be alerted about the possibility of sleep and awake bruxism activity in PD patients, along with this activity’s possible negative health outcomes (viz., TMD pain, tooth wear).
format Online
Article
Text
id pubmed-8060196
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-80601962021-05-05 Is dopaminergic medication dose associated with self-reported bruxism in Parkinson’s disease? A cross-sectional, questionnaire-based study Verhoeff, M. C. Koutris, M. van Selms, M. K. A. Brandwijk, A. N. Heres, M. S. Berendse, H. W. van Dijk, K. D. Lobbezoo, F. Clin Oral Investig Original Article OBJECTIVES: It is not clear whether dopaminergic medication influences bruxism behaviour in patients with Parkinson’s disease (PD). Therefore, the aims are to investigate (i) the prevalence of possible (i.e., self-reported) bruxism (sleep and awake) in PD patients, and (ii) whether the use of dopaminergic medication and other factors (viz., demographic characteristics, PD-related factors, and possible consequences of bruxism) are associated with possible bruxism (sleep or awake). MATERIALS AND METHODS: This study concerns a secondary analysis of an earlier published study. Three hundred ninety-five PD patients (67.9 ± 8.6 years of age; 58.7% males) were included. The levodopa equivalent daily dosage (LEDD) was used as a measure of the dopaminergic medication level. Subsequently, a logistic regression analysis was performed for the dependent variables ‘awake bruxism’ and ‘sleep bruxism’, with the following predictors: gender, age, LEDD, time since PD diagnosis, temporomandibular disorder (TMD) pain, jaw locks, and tooth wear. RESULTS: The prevalence of possible awake and sleep bruxism was 46.0% and 24.3%, respectively. Awake bruxism was associated with sleep bruxism (OR = 8.52; 95% CI 3.56–20.40), TMD pain (OR = 4.51; 95% CI 2.31–8.79), and tooth wear (OR = 1.87; 95% CI 1.02–3.43). Sleep bruxism was associated with tooth wear (OR = 12.49; 95% CI 4.97–31.38) and awake bruxism (OR = 9.48; 95% CI 4.24–21.19). Dopaminergic medication dose was not associated with awake bruxism (OR = 1.0; 95% CI 0.99–1.00) or sleep bruxism (OR = 1.0; 95% CI 0.99–1.00). CONCLUSION: Bruxism is a common condition in PD patients, but is not associated with the dopaminergic medication dose. CLINICAL RELEVANCE: (Oral) health care providers should be alerted about the possibility of sleep and awake bruxism activity in PD patients, along with this activity’s possible negative health outcomes (viz., TMD pain, tooth wear). Springer Berlin Heidelberg 2020-09-12 2021 /pmc/articles/PMC8060196/ /pubmed/32918624 http://dx.doi.org/10.1007/s00784-020-03566-0 Text en © The Author(s) 2020 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Original Article
Verhoeff, M. C.
Koutris, M.
van Selms, M. K. A.
Brandwijk, A. N.
Heres, M. S.
Berendse, H. W.
van Dijk, K. D.
Lobbezoo, F.
Is dopaminergic medication dose associated with self-reported bruxism in Parkinson’s disease? A cross-sectional, questionnaire-based study
title Is dopaminergic medication dose associated with self-reported bruxism in Parkinson’s disease? A cross-sectional, questionnaire-based study
title_full Is dopaminergic medication dose associated with self-reported bruxism in Parkinson’s disease? A cross-sectional, questionnaire-based study
title_fullStr Is dopaminergic medication dose associated with self-reported bruxism in Parkinson’s disease? A cross-sectional, questionnaire-based study
title_full_unstemmed Is dopaminergic medication dose associated with self-reported bruxism in Parkinson’s disease? A cross-sectional, questionnaire-based study
title_short Is dopaminergic medication dose associated with self-reported bruxism in Parkinson’s disease? A cross-sectional, questionnaire-based study
title_sort is dopaminergic medication dose associated with self-reported bruxism in parkinson’s disease? a cross-sectional, questionnaire-based study
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8060196/
https://www.ncbi.nlm.nih.gov/pubmed/32918624
http://dx.doi.org/10.1007/s00784-020-03566-0
work_keys_str_mv AT verhoeffmc isdopaminergicmedicationdoseassociatedwithselfreportedbruxisminparkinsonsdiseaseacrosssectionalquestionnairebasedstudy
AT koutrism isdopaminergicmedicationdoseassociatedwithselfreportedbruxisminparkinsonsdiseaseacrosssectionalquestionnairebasedstudy
AT vanselmsmka isdopaminergicmedicationdoseassociatedwithselfreportedbruxisminparkinsonsdiseaseacrosssectionalquestionnairebasedstudy
AT brandwijkan isdopaminergicmedicationdoseassociatedwithselfreportedbruxisminparkinsonsdiseaseacrosssectionalquestionnairebasedstudy
AT heresms isdopaminergicmedicationdoseassociatedwithselfreportedbruxisminparkinsonsdiseaseacrosssectionalquestionnairebasedstudy
AT berendsehw isdopaminergicmedicationdoseassociatedwithselfreportedbruxisminparkinsonsdiseaseacrosssectionalquestionnairebasedstudy
AT vandijkkd isdopaminergicmedicationdoseassociatedwithselfreportedbruxisminparkinsonsdiseaseacrosssectionalquestionnairebasedstudy
AT lobbezoof isdopaminergicmedicationdoseassociatedwithselfreportedbruxisminparkinsonsdiseaseacrosssectionalquestionnairebasedstudy